Business, energy, technology, markets and global industry news from Business News Today

BlossomHill Therapeutics

PharmaDeviceNews BlossomHill Therapeutics
A representative image illustrating BlossomHill Therapeutics’ BH-30643 lung cancer program as the FDA grants Fast Track designation for the investigational therapy targeting EGFR C797S-positive non-small cell lung cancer after resistance to third-generation EGFR inhibitors.
Pharma & Biotech

FDA Fast Track designation advances BH-30643 in C797S-positive lung cancer

BH-30643 gets FDA Fast Track status after early responses in C797S-positive lung cancer as BlossomHill expands the Phase 1/2 SOLARA trial.

Read More